GenesisCare continues to expand Spanishcancer services with Elekta

STOCKHOLM, October 25, 2016 – Elekta (EKTA-B.ST) announces that GenesisCare will
acquire Versa HD™ (http://www.elekta.com/versahd) linear accelerators to help
fulfil its ambition to improve cancer care for patients in Spain. The deal also
includes Elekta’s MOSAIQ® (https://www.elekta.com/mosaiq) oncology information
system to optimize the clinical care and operational efficiency of GenesisCare
in Spain.
Francois Pointurier, Elekta’s Senior Vice President Region EMEA, says: “Although
we have seen an increase in the incidence of cancer in Spain, the number of
cancer deaths has fallen, thanks in part to improved treatment using advanced
radiation therapy devices. We are proud to continue to partner with GenesisCare
as they expand in Spain and grow in the European market. GenesisCare will
receive the most advanced and recognized cancer treatment solutions on the
market. We look forward to providing the platforms to support GenesisCare’s
vision to provide accurate, efficient and high quality treatment.”

Following the recent acquisition of oncology groups, IMOncology and Oncosur,
GenesisCare is now the largest cancer care provider in Spain.

Dan Collins, Managing Director at GenesisCare, says: “By investing in the latest
technology and staff training we are providing our patients with access to more
efficient and effective care. This will enable our physicians and staff to offer
a smoother patient experience and improve patient outcomes. The suite of
advanced technology solutions, global influence and commitment to innovation
offered by Elekta will support our shared efforts to improve cancer services
across Spain.”

Versa HD is Elekta’s most advanced linear accelerator, used to accurately and
quickly deliver radiation therapy. MOSAIQ is a comprehensive oncology
information system that centralizes traditional radiation oncology, particle
therapy and medical oncology patient data into a single user interface,
accessible by multidisciplinary teams across multiple locations.

The total order is valued at EUR 25 million, of which approximately EUR 9.5
million was booked in the second quarter of Elekta’s fiscal year. This agreement
is in addition to an earlier deal with GenesisCare announced on March 31,
2016 (https://www.elekta.com/pressreleases/1127703/genesiscare-and-elekta-sign
-strategic-partnership-for-more-than-usd-100-million.html).

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

This information is information that Elekta AB (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication at 07:30 CET on October 25, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,600 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.

About GenesisCare
GenesisCare provides high quality specialist care to patients with cancer and
cardiovascular disease, the two largest disease burdens globally.

The organisation exists to improve quality and access for patients and
communities in need. The group is the largest provider of radiotherapy across
Australia, operating 27 cancer centres in major metropolitan and also regional
settings (including in tertiary teaching public hospitals). 80 locations provide
cardiology or sleep services. GenesisCare employs over 1700 highly trained
health professionals and support staff including more than 150 physicians and
leads, or participates, in approximately 100 clinical trials.

Cancer care is provided for all tumor groups with the latest techniques
including intensity modulated radiotherapy, volumetric arc therapy, stereotactic
radiotherapy and radiosurgery, low dose rate and high dose rate brachytherapy.

The GenesisCare medical team is comprised of some of the world’s most
experienced specialists with many dedicating time as consultants in public
hospitals or participating in research and teaching. GenesisCare adopts
internationally proven medical technologies integrated with electronic
healthcare records to improve patient clinical outcomes and their service
experience. Website: www.genesiscare.com.au